HCW Biologics (HCWB) shares more than doubled amid heavy trading after the company said Monday that it received US Food and Drug Administration clearance to launch a phase 1 trial to evaluate HCW9302 for treating moderate-to-severe alopecia areata.
Over 313.9 million shares traded intraday versus a daily average of roughly 9.9 million.
GH Research (GHRS) said Monday that a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.
Shares surged 82% as intraday trading volume catapulted to over 8.4 million from a daily average of about 79,000.
Triumph Group (TGI) said Monday that it agreed to be acquired and taken private by the affiliates of Warburg Pincus and Berkshire Partners in a roughly $3 billion all-cash deal.
Shares of the aerospace supplier jumped 34%, with intraday trading volume rising to over 14.4 million compared with a daily average of about 699,000.
Price: 0.66, Change: +0.39, Percent Change: +138.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.